PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
http://ww2.peerview.com
Robert Coleman, MD - Advances in Precision Care in Solid Tumor Oncology: Defining the Role of PARP Inhibitors
Go online to PeerView.com/RKN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The recent validation of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors in ovarian and breast cancer management and the emergence of early clinical data in prostate and pancreatic cancers promises a new era in targeted therapy, particularly in the subset of cancer patients harboring DNA-damage response (DDR) pathway mutations. In this 3-part activity, Robert Coleman, MD, Maha H.A. Hussain, MD, FACP, FASCO, and Mark E. Robson, MD discuss the rationale for targeting DDR pathways in cancer therapy and review recent safety and efficacy evidence with PARP inhibitors in patients with a range of solid tumor types. They also highlight companion diagnostics that can be used to identify patients across different cancers who might benefit from PARP inhibitor therapy and outline how these new regimens can be integrated into existing treatment paradigms. Upon completion of this activity, participants will be able to: Discuss DNA damage repair (DDR) pathways and the rationale for targeting DDR mutations with PARP inhibitors in cancer therapy, Assess the evidence on the safety and efficacy of PARP inhibitors across tumor types such as ovarian, breast, prostate, and pancreatic cancers, Describe the role of validated and emerging companion diagnostic assays to identify patient populations with different molecular subtypes across a range of cancers that might benefit with PARP inhibitor therapy, Integrate PARP inhibitors or novel therapeutic agents targeting DDR mutations into treatment plans for patients with cancer based on approved indications or in the context of clinical trials